Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases

Journal of the National Cancer Institute

Volumn 106, Issue 7, 2014, Pages

  Lee, Siow Ming ^a   Lewanski, Conrad R ^b   Counsell, Nicholas ^a   Ottensmeier, Christian ^c   Bates, Andrew ^c   Patel, Nirali ^a   Wadsworth, Christina ^a   Ngai, Yenting ^a   Hackshaw, Allan ^a   Faivre Finn, Corinne ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ERLOTINIB; PLACEBO;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRY SKIN; DYSARTHRIA; DYSPEPSIA; DYSPHASIA; DYSPNEA; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOTENSION; INFECTION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MULTICENTER STUDY; MUSCLE WEAKNESS; MYOPATHY; NAUSEA; OVERALL SURVIVAL; PAIN; PANCREATITIS; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; RECEPTOR GENE; SEIZURE; SOMNOLENCE; WILD TYPE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 84905218794     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju151     Document Type: Article

References (30)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973-2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865-2872.
2. Mamon HJ, Yeap BY, Janne, PA et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol. 2005;23(7):1530-1537.
3. Mujoomdar A, Austin JHM, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small-cell lung carcinoma: primary tumor size, cell type, and lymph node metastasis. Radiology. 2007;242(3):882-888.
4. Borgelt BN, Gelber R, Kramer S et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys.1980;6(1): 1-9
5. Gelber RD, Lorson M, Borgelt B, et al. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favourable prognosis. Cancer. 1981;48(8):1749-1753.
6. Kurtz JM, Gelber R, Brady LW, et al. The palliation of brain metastases in a favourable patient population: A randomised clinical trial by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1981;7(7):891-895.
7. Komarnicky LT, Phillips TL, Martz K et al. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys. 1991;20(1):53-58.
8. Sause WT, Scott C, Krisch R. et al. Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28. Int J Radiat Oncol Biol Phys. 1993;26(4):653-657.
9. Murray KJ, Scott C, Greenberg HM. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases. A report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys. 1997;39(3):571-574.
10. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial. Int J Radiat Oncol Biol Phys. 2005;61(1):185-191.
11. Caincross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol. 1980;7(6):529-541.
12. Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer. 1981;48(2):384-394.
13. Caincross JG, Posner JB. The management of brain metastases. In: Walker MD (ed). Oncology of the Nervous System. Boston, MA: Martinus Nijhoff; 1983:341.
14. Shepherd FA, Rodrigues-Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
15. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521-529.
16. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-742.
17. Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
18. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65(8):3328-3335.
19. Lai CS, Boshoff C, Falzon M, Lee SM. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax. 2006;61(1):91.
20. Weber B, Winterdahl M, Memon A, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thoracic Oncol. 2011;6(7):1287-1289.
21. Hata A, Kaji R, Fujita S, Katakami N. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thoracic Oncol. 2011;6(3):653-654.
22. Porta R, Sánchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624-631.
23. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-751.
24. Welsh JW, Komaki R, Amini A et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013;31(7):895-902.
25. Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77(3):556-560.
26. Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70(3):399-405.
27. Katayama T, Shimizu J, Suda K et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009;4(11):1415-1419.
28. Villalva C, Duranton-Tanneur V, Guilloteau K. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. Cancer Med. 2013;2(3):296-304.
29. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6(1):1-9.
30. Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012;4:CD003869